LENZ vs. GLUE

Last updated Apr 1, 2026

Compare and contrast key facts about LENZ Therapeutics Inc (LENZ) and Monte Rosa Therapeutics, Inc. (GLUE).

Performance

LENZ vs. GLUE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in LENZ Therapeutics Inc (LENZ) and Monte Rosa Therapeutics, Inc. (GLUE). The values are adjusted to include any dividend payments, if applicable.

LENZ vs. GLUE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
LENZ LENZ Therapeutics Inc	-42.81%	-44.58%	230.71%	-21.08%	-73.29%	-32.81%
GLUE Monte Rosa Therapeutics, Inc.	4.91%	125.94%	22.83%	-25.76%	-62.73%	8.27%

Fundamentals

EPS LENZ : -$2.81 GLUE : -$0.72
PS Ratio LENZ : 14.01 GLUE : 7.30
Total Revenue (TTM) LENZ : $19.09M GLUE : $123.67M
Gross Profit (TTM) LENZ : $18.55M GLUE : $118.80M
EBITDA (TTM) LENZ : -$88.77M GLUE : -$45.22M

Returns By Period

In the year-to-date period, LENZ achieves a -42.81% return, which is significantly lower than GLUE's 4.91% return.

LENZ

• 1D: 10.37%
• 1M: -32.17%
• YTD: -42.81%
• 6M: -80.36%
• 1Y: -64.41%
• 3Y*: 3.88%
• 5Y*: —
• 10Y*: —

GLUE

• 1D: 5.92%
• 1M: -7.32%
• YTD: 4.91%
• 6M: 122.00%
• 1Y: 254.53%
• 3Y*: 28.29%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LENZ vs. GLUE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LENZ

LENZ Risk / Return Rank: 10
LENZ Sharpe Ratio Rank: 9
LENZ Sortino Ratio Rank: 10
LENZ Omega Ratio Rank: 11
LENZ Calmar Ratio Rank: 13
LENZ Martin Ratio Rank: 9

GLUE

GLUE Risk / Return Rank: 94
GLUE Sharpe Ratio Rank: 95
GLUE Sortino Ratio Rank: 96
GLUE Omega Ratio Rank: 92
GLUE Calmar Ratio Rank: 94
GLUE Martin Ratio Rank: 93

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LENZ vs. GLUE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for LENZ Therapeutics Inc (LENZ) and Monte Rosa Therapeutics, Inc. (GLUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LENZ	GLUE	Difference
Sharpe ratio Return per unit of total volatility	-0.77	2.68	-3.45
Sortino ratio Return per unit of downside risk	-1.06	3.77	-4.84
Omega ratio Gain probability vs. loss probability	0.87	1.43	-0.56
Calmar ratio Return relative to maximum drawdown	-0.77	5.32	-6.09
Martin ratio Return relative to average drawdown	-1.52	12.85	-14.37
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LENZ vs. GLUE - Sharpe Ratio Comparison

The current LENZ Sharpe Ratio is -0.77, which is lower than the GLUE Sharpe Ratio of 2.68. The chart below compares the historical Sharpe Ratios of LENZ and GLUE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LENZ	GLUE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.77	2.68	-3.45
Sharpe Ratio (All Time) Calculated using the full available price history	-0.43	-0.05	-0.38

Correlation

The correlation between LENZ and GLUE is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LENZ vs. GLUE - Dividend Comparison

Neither LENZ nor GLUE has paid dividends to shareholders.

	TTM	2025	2024
LENZ LENZ Therapeutics Inc	0.00%	0.00%	28.54%
GLUE Monte Rosa Therapeutics, Inc.	0.00%	0.00%	0.00%

Drawdowns

LENZ vs. GLUE - Drawdown Comparison

The maximum LENZ drawdown since its inception was -93.98%, roughly equal to the maximum GLUE drawdown of -94.08%. Use the drawdown chart below to compare losses from any high point for LENZ and GLUE.

Drawdown Indicators

	LENZ	GLUE	Difference
Max Drawdown Largest peak-to-trough decline	-93.98%	-94.08%	+0.10%
Max Drawdown (1Y) Largest decline over 1 year	-83.10%	-41.84%	-41.26%
Current Drawdown Current decline from peak	-91.06%	-61.03%	-30.03%
Average Drawdown Average peak-to-trough decline	-78.15%	-75.32%	-2.83%
Ulcer Index Depth and duration of drawdowns from previous peaks	42.24%	17.32%	+24.92%

Volatility

LENZ vs. GLUE - Volatility Comparison

LENZ Therapeutics Inc (LENZ) has a higher volatility of 28.71% compared to Monte Rosa Therapeutics, Inc. (GLUE) at 14.31%. This indicates that LENZ's price experiences larger fluctuations and is considered to be riskier than GLUE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LENZ	GLUE	Difference
Volatility (1M) Calculated over the trailing 1-month period	28.71%	14.31%	+14.40%
Volatility (6M) Calculated over the trailing 6-month period	68.04%	63.89%	+4.15%
Volatility (1Y) Calculated over the trailing 1-year period	83.50%	96.16%	-12.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	77.25%	102.69%	-25.44%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.25%	102.69%	-25.44%

Financials